Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$1.50M-11.88%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Rachel E. Haurwitz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 97
- Beta
- 2.28
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.26
Financials
Revenue
$1.50M-11.9%Net Income
$-24.28MEBITDA
$-26.40MFree Cash Flow
$-22.79MEPS (diluted)
$-0.24Shares Outstanding (diluted)
100.99M+265.1%Operating Expenses
$26.84MCash & Debt
$112.31MRevenue by Segment (annual)
$11.16MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.16M | $-148.13M | $-1.59 |
| 2024 | $9.99M | $-149.10M | $-1.65 |
| 2023 | $34.48M | $-102.07M | $-1.38 |
| 2022 | $13.85M | $-99.42M | $-1.64 |
| 2021 | $9.60M | $-66.92M | $-1.11 |
| 2020 | $12.36M | $-34.31M | $-1.24 |
| 2019 | $5.79M | $-23.43M | $-0.85 |
Valuation
CRBUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
Caribou Biosciences to Evaluate Strategic Alternatives -- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --
View source ↗ - Newszacks.com·22d ago·Neutral
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
View source ↗ - Newszacks.com·54d ago·Negative
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.35 per share a year ago.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.29 per share
Typical surprise +15.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.24 vs $-0.32beat
- Thu, May 7$-0.26 vs $-0.33beat
- Thu, Mar 5$-0.28 vs $-0.33beat
- Wed, Nov 12$-0.30 vs $-0.36beat
- Tue, Aug 12$-0.35 vs $-0.40beat
- Thu, May 8$-0.43 vs $-0.43beat
Estimates and results for CRBU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRBU officers and directors.
- Bought
- $45k
- Sold
- $97k
2 trades
9 trades
- Kelly Timothy Psold
- Kelly Timothy Psold
- Mcclung Barbara Gsold
- Khan Ruhi Ahmadsold
- Albertson Tina M.sold
- Haurwitz Rachel E.bought
- Mcclung Barbara Gsold
- Khan Ruhi Ahmadsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CRBU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.